Eric Peters

Eric Peters is currently Executive Director and Head of Companion Diagnostics within Oncology Biomarker Development (OBD) at Genentech. His group is responsible for the development and implementation of CDx strategies to further the molecule development pipeline across all disease areas. His group works closely with internal and external diagnostic partners, molecule teams, and other functions across the company to ensure success of our CDx assay and platform development strategies. Prior to joining Genentech in December of 212, Eric was a project team leader at Illumina. While there, he led a team focused on the development of next-generation diagnostic and CDx assays and platforms. His work includes leading the team responsible for the development of the first FDA-cleared NGS platform (MiSeqDx). Eric obtained a PhD in Pharmaceutical Sciences and Pharmacogenomics from the University of California at San Francisco. He subsequently completed postdoctoral training in cancer pharmacogenomics at the University of North Carolina.